1 minute read
The U.S. Food and Drug Administration’s (FDA) advisory panel has endorsed an Emergency Use Authorization (EUA) for Pfizer’s COVID-19 vaccine for widespread use. Next, the FDA will need to approve the vaccine for EUA. The authorization is likely to be issued within days, giving health care workers and long-term care residents first priority in receiving the vaccine.
The advisory committee who issued the endorsement is composed of scientists, independent doctors, and experts. The endorsement follows a recommendation from the Centers for Disease Control and Prevention (CDC) for a COVID-19 distribution plan.
It may take months before the vaccine is available to the general public. So, employers should plan for the pandemic to continue and await additional guidance about what a vaccine authorization will mean for workplaces. Download the bulletin for additional information.
This blog is intended to be a compilation of information and resources pulled from federal, state, and local agencies. This is not intended to be legal advice. For up to the minute information and guidance on COVID-19, please follow the guidelines of the Centers for Disease Control and Prevention (CDC) and your local health organizations.
National Insurance Services is not a law firm and no opinion, suggestion, or recommendation of the firm or its employees shall constitute legal advice. Readers are advised to consult with their own attorney for a determination of their legal rights, responsibilities and liabilities, including the interpretation of any statute or regulation, or its application to the readers’ business activities.
